https://orcid.org/0000-0002-7071-4637My research program is focused on drug discovery, preclinical and clinical development for the potential launch of pharmaceuticals and natural health products. My research group conducts investigations in the therapeutic areas of neurodegenerative diseases, ocular diseases, infectious diseases, metabolic and hematological disorders. Currently, we are developing novel stereoisomers of cannabidiol, novel small molecule inhibitors targeting cytopenias including ITP, antivirals targeting the BK virus in kidney transplant, clinical trials of KP-302 (Lucid-21-302) for progressive multiple sclerosis, and profiling of cannabinoids in osteoarthritis patients.